Examine the evolution of Hologic's (HOLX) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HOLX's fiscal 2025 first-quarter results reflect the strength of its Molecular Diagnostics business.
Hologic, Inc. (NASDAQ:HOLX ) Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Mike Watts - Corporate Vice President, IR Steve MacMillan - Chairman, President and CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Anthony Petrone - Mizuho Group Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Tycho Peterson - Jefferies Casey Woodring - JP Morgan Tejas Savant - Morgan Stanley Ryan Zimmerman - BTIG Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Andrew Cooper - Raymond James Operator Good afternoon. And welcome to the Hologic's First Quarter Fiscal 2025 Earnings Conference Call.
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.98 per share a year ago.
Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company's shares down 5% after the bell on Wednesday.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.